FDA Idvynso FDA approval has officially declared by Merck (known as MSD outside the U.S. and Canada) for its new, once-daily single-tablet regimen. This treatment, a combination of 100 mg doravirine and 0.25 mg islatravir, is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen. This landmark Idvynso FDA approval introduces the first and only non-INSTI (integrase strand transfer inhibitor), tenofovir-free, complete two-drug regimen to demonstrate non-inferior efficacy in head-to-head Phase 3 trials.
The Significance of Idvynso FDA Approval in HIV Care
The Idvynso FDA approval provides a critical alternative for patients looking to simplify their treatment without compromising efficacy. For many years, three-drug regimens including tenofovir have been the standard of care. However, as the population of people living with HIV ages, there is an increasing demand for regimens with fewer drugs and improved long-term tolerability profiles.
Clinical Trial Data Supporting Idvynso FDA Approval
The Idvynso FDA approval was based on robust data from two pivotal Phase 3 trials: Trial 052 (NCT05630755) and Trial 051 (NCT05631093). These studies evaluated the safety and efficacy of switching to the doravirine/islatravir combination compared to maintaining current antiretroviral therapy (ART).
Trial 052 Efficacy Results (Switch from Biktarvy)
| Endpoint (Week 48) | Idvynso (N=342) | Biktarvy (N=171) | Treatment Difference (95% CI) |
| HIV-1 RNA ≥50 copies/mL | 1% | 1% | 0.0% (-1.9% to 2.9%) |
| HIV-1 RNA <50 copies/mL | 92% | 94% | -1.4% (-5.5% to 2.3%) |
Trial 051 Efficacy Results (Switch from Baseline ART)
| Endpoint (Week 48) | Idvynso (N=367) | Baseline ART (N=184) | Treatment Difference (95% CI) |
| HIV-1 RNA ≥50 copies/mL | 1% | 5% | -3.8% (-7.0% to -0.6%) |
| HIV-1 RNA <50 copies/mL | 96% | 92% | 3.5% (-0.9% to 8.4%) |
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Safety and Dosing Information
Following the Idvynso FDA approval, clinicians have noted that the regimen is generally well-tolerated. Common adverse reactions reported in clinical trials included diarrhea, dizziness, fatigue, and headache. It is important to note that Idvynso is contraindicated when co-administered with strong CYP3A enzyme inducers, as they may significantly decrease the effectiveness of the medication.
